The risk of menopausal symptoms in premenopausal breast cancer patients and current pharmacological prevention strategies

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Azim HA Jr., Partridge AH. Biology of breast cancer in young women. BCR. 2014 Aug 27;16(4):427.
   PubMed Web of Science ®Google Scholar
• Anders CK, Fan C, Parker JS, et al. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol. 2011 Jan 1;29(1):e18–20.
   PubMed Web of Science ®Google Scholar
• Azim HA Jr., Michiels S, Bedard PL, et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012 Mar 1;18(5):1341–1351.
   PubMed Web of Science ®Google Scholar
• Fidler MM, Gupta S, Soerjomataram I, et al. Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study. Lancet Oncol. 2017 Dec;18(12):1579–1589.
   PubMed Web of Science ®Google Scholar
• Paluch-Shimon S, Cardoso F, Partridge AH, et al. ESO-ESMO 4th international consensus guidelines for breast cancer in young women (BCY4). Ann Oncol. 2020 Mar 19;31(6):674–696.
   Web of Science ®Google Scholar
• Yeo W, Lee HM, Chan A, et al. Risk factors and natural history of breast cancer in younger Chinese women. World J Clin Oncol. 2014 Dec 10;5(5):1097–1106.
   PubMedGoogle Scholar
• Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016 May;31(5):926–937.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Amant F, Braat D, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020(4):hoaa052. 2020.
   PubMedGoogle Scholar
• Lambertini M, Peccatori FA, Demeestere I, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2020 Dec;31(12):1664–1678.
   PubMed Web of Science ®Google Scholar
• Yeo W, Pang E, Liem GS, et al. Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors. Health Qual Life Outcomes. 2020 Feb 10;18(1):24.
   PubMed Web of Science ®Google Scholar
• Research on the menopause in the 1990s. Report of a WHO scientific group. World Health Organization technical report series. 1996;866:1–107.
   Google Scholar
• Bacon JL. The menopausal transition. Obstet Gynecol Clin North Am. 2017 Jun;44(2):285–296.
   PubMed Web of Science ®Google Scholar
• Shifren JL, Gass ML. The North American menopause society recommendations for clinical care of midlife women. Menopause. 2014 Oct;21(10):1038–1062.
   PubMed Web of Science ®Google Scholar
• Aidelsburger P, Schauer S, Grabein K, et al. Alternative methods for the treatment of post-menopausal troubles. GMS Health Technol Assess. 2012;8:Doc03.
   PubMedGoogle Scholar
• Kaunitz AM, Manson JE. Management of menopausal symptoms. Obstet Gynecol. 2015 Oct;126(4):859–876.
   PubMed Web of Science ®Google Scholar
• Rance NE, Dacks PA, Mittelman-Smith MA, et al. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: a novel hypothesis on the mechanism of hot flushes. Front Neuroendocrinol. 2013 Aug;34(3):211–227.
   PubMed Web of Science ®Google Scholar
• Kupperman HS, Blatt MH, Wiesbader H, et al. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol Metab. 1953 Jun;13(6):688–703.
   PubMed Web of Science ®Google Scholar
• Zöllner YF, Acquadro C, Schaefer M. Literature review of instruments to assess health-related quality of life during and after menopause. Qual Life Res. 2005 Mar;14(2):309–327.
   PubMed Web of Science ®Google Scholar
• Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas. 1996 Jul;24(3):161–175.
   PubMed Web of Science ®Google Scholar
• Dorjgochoo T, Gu K, Kallianpur A, et al. Menopausal symptoms among breast cancer patients 6 months after diagnosis: a report from the Shanghai breast cancer survival study. Menopause. 2009 Nov-Dec;16(6):1205–1212.
   PubMed Web of Science ®Google Scholar
• Mazor M, Cataldo JK, Lee K, et al. Influence of menopausal status on the symptom experience of women before breast cancer surgery. Cancer Nurs. 2018 Jul-Aug;41(4):265–278.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Blondeaux E, Perrone F, et al. Improving adjuvant endocrine treatment tailoring in premenopausal women with hormone receptor-positive breast cancer. J Clin Oncol. 2020 Apr 20;38(12):1258–1267.
   PubMed Web of Science ®Google Scholar
• Loibl S, Lintermans A, Dieudonne AS, et al. Management of menopausal symptoms in breast cancer patients. Maturitas. 2011 Feb;68(2):148–154.
   PubMed Web of Science ®Google Scholar
• Lammerink EA, De Bock GH, Schroder CP, et al. The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas. 2012 Nov;73(3):265–268.
   PubMed Web of Science ®Google Scholar
• Franzoi MA, Agostinetto E, Perachino M, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. Publishe on 2021 Apr 20. DOI:https://doi.org/10.1016/S1470-2045(20)30666-5.
   Google Scholar
• Fujii T, Le Du F, Xiao L, et al. Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: a systematic review and network meta-analysis. JAMA Oncol. 2015 Dec;1(9):1311–1318.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Version 2. 2021. cited 2021 Mar 23. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011 Aug 27;378(9793):771–784.
   PubMed Web of Science ®Google Scholar
• Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J clin oncol. 2013 Jun 20;31(18_suppl):5.
   PubMed Web of Science ®Google Scholar
• Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805–816.
   PubMed Web of Science ®Google Scholar
• Miller WR, Anderson TJ, Dixon JM. Anti-tumor effects of letrozole. Cancer Invest. 2002;20(Suppl 2):15–21.
   PubMed Web of Science ®Google Scholar
• Hadji P, Kauka A, Bauer T, et al. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German substudy. Climacteric J Int Menopause Soc. 2012 Oct;15(5):460–466.
   PubMed Web of Science ®Google Scholar
• Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res. 1997 Jul;3(7):1101–1108.
   PubMed Web of Science ®Google Scholar
• Casper RF. Aromatase inhibitors in ovarian stimulation. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1–5):71–75.
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006 Jun 1;24(16):2444–2447.
   PubMed Web of Science ®Google Scholar
• Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018 Jul 12;379(2):122–137.
   PubMed Web of Science ®Google Scholar
• Marino JL, McNamara HC, Hickey M. Managing menopausal symptoms after cancer: an evidence-based approach for primary care. Med J Aust. 2018 Feb 19;208(3):127–132.
   PubMed Web of Science ®Google Scholar
• Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012 Mar 7;104(5):386–405.
   PubMedGoogle Scholar
• Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003 May 30;45(1):29–38.
   PubMed Web of Science ®Google Scholar
• Leining MG, Gelber S, Rosenberg R, et al. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol. 2006 Dec;17(12):1777–1782.
   PubMed Web of Science ®Google Scholar
• Nystedt M, Berglund G, Bolund C, et al. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2003 May 1;21(9):1836–1844.
   PubMed Web of Science ®Google Scholar
• Dowsett M, Folkerd E, Doody D, et al. The biology of steroid hormones and endocrine treatment of breast cancer. Breast. 2005 Dec;14(6):452–457.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479–484.
   PubMed Web of Science ®Google Scholar
• Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat. 2007;105(Suppl1):7–17.
   PubMed Web of Science ®Google Scholar
• Santen RJ, Stuenkel CA, Davis SR, et al. Managing menopausal symptoms and associated clinical issues in breast cancer survivors. J Clin Endocrinol Metab. 2017;102(10):3647–3661.
   PubMed Web of Science ®Google Scholar
• Hong D, Bi L, Zhou J, et al. Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors. Oncotarget. 2017;8(25):40558–40567.
   Google Scholar
• Cheer SM, Plosker GL, Simpson D, et al. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs. 2005;65(18):2639–2655.
   PubMed Web of Science ®Google Scholar
• Berglund G, Nystedt M, Bolund C, et al. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2001 Jun 1;19(11):2788–2796.
   PubMed Web of Science ®Google Scholar
• Tevaarwerk AJ, Wang M, Zhao F, et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern cooperative oncology group. J Clin Oncol. 2014 Dec 10;32(35):3948–3958.
   PubMed Web of Science ®Google Scholar
• Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29;372(5):436–446.
   PubMed Web of Science ®Google Scholar
• Ribi K, Luo W, Bernhard J, et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol. 2016 May 10;34(14):1601–1610.
   PubMed Web of Science ®Google Scholar
• Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107–118.
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, De Vecchis L, et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol. 2014 Jan;89(1):27–42.
   PubMed Web of Science ®Google Scholar
• Myers SE, Schilsky RL. Prospects for fertility after cancer chemotherapy. Semin Oncol. 1992 Oct;19(5):597–604.
   PubMed Web of Science ®Google Scholar
• Yuksel A, Bildik G, Senbabaoglu F, et al. The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells. Hum Reprod. 2015 Dec;30(12):2926–2935.
   PubMed Web of Science ®Google Scholar
• Zhao J, Liu J, Chen K, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2014 May;145(1):113–128.
   PubMed Web of Science ®Google Scholar
• Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol. 2016 Jun;55(6):664–670.
   PubMed Web of Science ®Google Scholar
• Ganz PA, Land SR, Geyer CE Jr., et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011 Mar 20;29(9):1110–1116.
   PubMed Web of Science ®Google Scholar
• Sukumvanich P, Case LD, Van Zee K, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer. 2010 Jul 1;116(13):3102–3111.
   PubMed Web of Science ®Google Scholar
• Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010 Feb 15;116(4):791–798.
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302–2313.
   PubMed Web of Science ®Google Scholar
• Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006 Mar 1;24(7):1045–1051.
   PubMed Web of Science ®Google Scholar
• Poorvu PD, Frazier AL, Feraco AM, et al. Cancer treatment-related infertility: a critical review of the evidence. JNCI Cancer Spectr. 2019 Mar;3(1): pkz008.
   PubMed Web of Science ®Google Scholar
• Yoo C, Yun MR, Ahn JH, et al. Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study. Cancer Chemother Pharmacol. 2013 Sep;72(3):565–575.
   PubMed Web of Science ®Google Scholar
• Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005 Oct 15;104(8):1575–1579.
   PubMed Web of Science ®Google Scholar
• Han HS, Ro J, Lee KS, et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009 May;115(2):335–342.
   PubMed Web of Science ®Google Scholar
• Okanami Y, Ito Y, Watanabe C, et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011 Jul;18(3):182–188.
   PubMed Web of Science ®Google Scholar
• Najafi S, Djavid GE, Mehrdad N, et al. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea. Menopause. 2011 Feb;18(2):208–212.
   PubMed Web of Science ®Google Scholar
• Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007 Apr;30(2):126–132.
   PubMed Web of Science ®Google Scholar
• Minisini AM, Menis J, Valent F, et al. Determinants of recovery from amenorrhea in premenopausal breast cancer patients receiving adjuvant chemotherapy in the taxane era. Anticancer Drugs. 2009 Jul;20(6):503–507.
   PubMed Web of Science ®Google Scholar
• Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008 Nov;90(5):1635–1639.
   PubMed Web of Science ®Google Scholar
• Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010 Dec 15;102(24):1845–1854.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Ceppi M, Cognetti F, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies. Eur J Cancer. 2017 Jan;71:34–42.
   PubMed Web of Science ®Google Scholar
• Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018 Jul 1;29(7):1497–1508.
   PubMed Web of Science ®Google Scholar
• Sharma PRL, Rock L, Kimler BF, et al. Chemotherapy-induced amenorrhea (CIA) risk associated with taxane/platinum-based chemotherapy in young (≤45 years) breast cancer patients. J Clin Oncol. 2014;32(suppl):9592.
   Web of Science ®Google Scholar
• Lambertini M, Campbell C, Bines J, et al. Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. JNCI: Journal of the National Cancer Institute. 2019 Jan 1;111(1):86–94.
   PubMedGoogle Scholar
• Berliere M, Duhoux FP, Dalenc F, et al. Tamoxifen and ovarian function. PLoS One. 2013;8(6):e66616.
   PubMed Web of Science ®Google Scholar
• Kim H, Han W, Ku SY, et al. Feature of amenorrhea in postoperative tamoxifen users with breast cancer. J Gynecol Oncol. 2017;28(2):e10–e10.
   PubMed Web of Science ®Google Scholar
• Di Cosimo S, Alimonti A, Ferretti G, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004 Jul;15(7):1065–1071.
   PubMed Web of Science ®Google Scholar
• Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat. 2009 Jan;113(2):315–320.
   PubMed Web of Science ®Google Scholar
• Jung M, Shin HJ, Rha SY, et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. Ann Surg Oncol. 2010 Dec;17(12):3259–3268.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Mansi J, Coleman RE, et al. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017 Dec;87:58–64.
   PubMed Web of Science ®Google Scholar
• Dezellus A, Barriere P, Campone M, et al. Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer. Eur J Cancer. 2017 Jul;79:72–80.
   PubMed Web of Science ®Google Scholar
• Shandley LM, Spencer JB, Fothergill A, et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril. 2017 Jan;107(1):243–252.e5.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Olympios N, Lequesne J, et al. Impact of taxanes, endocrine therapy, and deleterious germline BRCA mutations on anti-müllerian hormone levels in early breast cancer patients treated with anthracycline- and cyclophosphamide-based chemotherapy. Front Oncol. 2019;9:575.
   PubMed Web of Science ®Google Scholar
• Goldfarb SB, Turan V, Bedoschi G, et al. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Res Treat. 2021 Jan;185(1):165–173.
   PubMed Web of Science ®Google Scholar
• Ruddy KJ, Guo H, Barry W, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun;151(3):589–596.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Horicks F, Del Mastro L, et al. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: from biological evidence to clinical application. Cancer Treat Rev. 2019 Jan;72:65–77.
   PubMed Web of Science ®Google Scholar
• Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016 Jan;2(1):65–73.
   PubMed Web of Science ®Google Scholar
• Sun JRY, Li W. Effect of zoladex administered before chemotherapy on menstruation of patients with breast cancer. China Disabil Med. 2011;19:15–16.
   Google Scholar
• Li MY, Huang H, Liang Y, et al. Effect of Zoladex administered before chemotherapy on menstruation of patients with breast cancer. Chin J Clin Oncol. 2008 Jan 1;35:905–907.
   Google Scholar
• Badawy A, Elnashar A, El-Ashry M, et al. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril. 2009 Mar;91(3):694–697.
   PubMed Web of Science ®Google Scholar
• Sverrisdottir A, Nystedt M, Johansson H, et al. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. 2009 Oct;117(3):561–567.
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. Jama. 2011 Jul 20;306(3):269–276.
   PubMed Web of Science ®Google Scholar
• Gerber B, Von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011 Jun 10;29(17):2334–2341.
   PubMed Web of Science ®Google Scholar
• Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Feb 10;30(5):533–538.
   PubMed Web of Science ®Google Scholar
• Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013 Jan;121(1):78–86.
   PubMed Web of Science ®Google Scholar
• Jiang FY, Zhang QQ, Zeng J. Protective effect of GnRHa on chemotherapy induced ovarian damage in breast cancer patients. Shandong Med J. 2013;53(8):16–18.
   Google Scholar
• Song G, Gao H, Yuan Z. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. Med Oncol. 2013;30(3):667.
   PubMed Web of Science ®Google Scholar
• Karimi-Zarchi M, Forat-Yazdi M, Vafaeenasab MR, et al. Evaluation of the effect of GnRH agonist on menstrual reverse in breast cancer cases treated with cyclophosphamide. Eur J Gynaecol Oncol. 2014;35(1):59–61.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Boni L, Michelotti A, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. Jama. 2015 Dec 22-29;314(24):2632–2640.
   PubMed Web of Science ®Google Scholar
• Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923–932.
   PubMed Web of Science ®Google Scholar
• Leonard RCF, Adamson DJA, Bertelli G, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the anglo celtic group OPTION trial. Ann Oncol. 2017 Aug 1;28(8):1811–1816.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ji Y, Li J, et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res Treat. 2018 Apr;168(3):679–686.
   PubMed Web of Science ®Google Scholar
• Moore HCF, Unger JM, Phillips KA, et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230. J Natl Cancer Inst. 2019 Feb 1;111(2):210–213.
   PubMedGoogle Scholar
• Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015 Dec;26(12):2408–2419.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018 Jul 1;36(19):1981–1990.
   PubMed Web of Science ®Google Scholar
• Oktay K, Rodriguez-Wallberg K, Munster P. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015 Jun 4;372(23):2268–2269.
   PubMed Web of Science ®Google Scholar
• Mathews TJ, Hamilton BE. Mean age of mothers is on the rise: United States, 2000-2014. NCHS Data Brief. 2016 Jan;(232):1–8.
   Google Scholar
• Azim HA Jr., Santoro L, Pavlidis N, et al. Safety of pregnancy following breast cancer diagnosis: a meta-analysis of 14 studies. Eur J Cancer. 2011 Jan;47(1):74–83.
   PubMed Web of Science ®Google Scholar
• Azim HA Jr., Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013 Jan 1;31(1):73–79.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Kroman N, Ameye L, et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst. 2018 Apr 1;110(4):426–429.
   PubMedGoogle Scholar
• Lambertini M, Martel S, Campbell C, et al. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019 Jan 15;125(2):307–316.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Ameye L, Hamy A-S, et al. Pregnancy after breast cancer in patients with germline BRCA mutations. J Clin Oncol. 2020 Sep 10;38(26):3012–3023.
   PubMed Web of Science ®Google Scholar
• Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018 Jul 1;36(19):1994–2001.
   PubMed Web of Science ®Google Scholar
• Vriens IJH, Ter Welle-Butalid EM, De Boer M, et al. Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience. Breast Cancer Res Treat. 2020 May;181(1):77–86.
   PubMed Web of Science ®Google Scholar
• Marklund A, Eloranta S, Wikander I, et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. Hum Reprod. 2020 Apr 28;35(4):929–938.
   PubMed Web of Science ®Google Scholar
• Marklund A, Lundberg FE, Eloranta S, et al. Reproductive outcomes after breast cancer in women with vs without fertility preservation. JAMA Oncol. 2021 Jan 1;7(1):86-91.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Dellepiane C, Viglietti G, et al. Pharmacotherapy to protect ovarian function and fertility during cancer treatment. Expert Opin Pharmacother. 2017 Jun;18(8):739–742.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Cinquini M, Moschetti I, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian association of medical oncology. Eur J Cancer. 2017 Jan;71:25–33.
   PubMed Web of Science ®Google Scholar
• Thomas A, Rhoads A, Pinkerton E, et al. Incidence and survival among young women with Stage I-III breast cancer: SEER 2000-2015. JNCI Cancer Spectr. 2019 Sep;3(3): pkz040.
   Web of Science ®Google Scholar
• Youlden DR, Cramb SM, Yip CH, et al. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014 Jun;11(2):101–115.
   PubMedGoogle Scholar
• Ruggeri M, Pagan E, Bagnardi V, et al. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: baseline results from an ongoing prospective cohort study in selected European Centers. Breast. 2019 Oct;47:85–92.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Rosen MP. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer. Jama. 2011 Jul 20;306(3):312–314.
   PubMed Web of Science ®Google Scholar
• Regan MM, Walley BA, Francis PA, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017 Sep 1;28(9):2225–2232.
   PubMed Web of Science ®Google Scholar